Technology Transfer for the Max Planck Society
Max Planck Innovation is responsible for technology transfer from the research institutes of the Max Planck Society.
The Max Planck Society (MPG) operates as Germany’s most successful organization in basic research and is worldrenowned for its cutting-edge research. In many cases this cutting-edge research also forms the basis for innovative products and services that are implemented through licensing and spin-off companies.
Thus we perform an important task: the transfer of basic research results into products, which contribute to the economic and social progress.
50 years of Max Planck innovation - 50 years of technology transfer for the Max Planck Society
We are your contact for
We advise and support scientists in the evaluation and patenting of research results while helping to establish the best success in the market.
Do you have a business idea? If so, talk to us! We offer founders a comprehensive range of services from evaluating a spin-off project through to fundraising support.
We provide future-oriented companies with access to the patented inventions and know-how of the Max Planck Institutes and offer them licensing opportunities.
Multifunctional RFID-based Platform for Animal Observation and Manipulation
Bioinspired Liquid-Superrepellent Fibrillar Dry Adhesives
Novel method for analysis of complex carbohydrate structures by ion-mobility mass spectrometry (IM-MS)
Novel protein expression optimization method combining machine learning with insights from mechanistic modelling of mRNA translation
High-precision base editors for site-specific single nucleotide conversion
First in class “semi-live” RNA vaccines against SARS-CoV-2, RSV and other respiratory viruses
A novel type of influenza A virus-derived Defective interfering Particle for antiviral therapy
Method for the Calibration of a Microscope Setup
FLASH 2 is well received in research
New MRI procedure offers immense advantages in pediatric radiology
BiondVax signs exclusive license agreement
Novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases
7 million euros for MPG spin-out Proxima Fusion
Development of fusion power plants as a clean and reliable energy source
MPG spin-off Thermosome starts Phase I trial
First patient dosed with lead program THE001 for the treatment of soft tissue sarcoma
New method for micromanipulation goes into practice
With FLUCS, the development of embryos can be controlled
Life Science Inventions on the Biovaria
Innovative technologies with high potential for pharmaceutical and biotech companies
Max Planck Innovation presents 10 start-ups from basic research at new event format for investors.
225 million euros for Max Planck innovation start-ups
The successful business year for Max Planck Innovation includes increasing investment amounts for the start-ups supported.
Newsletter Sign up
Sign up for our newsletter and our press releases and receive the latest information on technology transfer from the Max Planck Society: Sign up